- Revolution Medicines shares promising data around KRAS drug combinationRevolution Medicines on Thursday gave a first look at the early-stage data that led it to plan a Phase 3 trial combining two KRAS drugs in pancreatic cancer. One of the two drugs is a ...Endpoints · 22d ago↗ source
- Otsuka reports long-term kidney data key to Voyxact's bid for full approvalOtsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabil…Endpoints · 22d ago↗ source
- IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, SeaportWith major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics. Celea has corralled $180 million to see if